Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP)
While Adaptimmune Therapeutics is currently taking a dive, the stock is likely to have a strong day in the market throughout the day. Just minutes ago, in the midst of the declines, the company made a key announcement surrounding a collaboration. Today, we’ll talk about the collaboration, what we’re seeing in the market, and what we can expect to see from ADAP ahead.
Trade smarter and make more money with Tradespoon!
ADAP Enters Into A Collaboration Agreement With Merck & Co.
As mentioned above, just minutes ago, Adaptimmune Therapeutics announced a new collaboration agreement. The agreement was signed with Merck & Co., also known as MSD outside of the US and Canada. The agreement surrounds the assessment of NY-ESO SPEAR T-cell therapy from ADAP in combination with KEYTRUDA, MSD’s anti-grogrammed death-1 inhibitor. The combination treatment is designed for patients dealing with multiple myeloma. In a statement, Rafael Amado, CMO at ADAP, had the following to offer:
“In initial single-agent studies of our NY-SEO SPEAR T-cell therapy in patients with advanced myeloma in the context of stem cell transplantation, we have seen encouraging evidence of antitumor effect, safe administration and prolonged persistence of transduced cells… KEYTRUDA has shown preliminary evidence of activity in multiple myeloma, and there is preclinical evidence to support the view that the combination of NY-ESO SPEAR T-cell therapy and anti-PD1 therapy may lead to meaningful anti-tumor activity. We look forward to evaluating our therapy alone and in combination with KEYTRUDA in a randomized trial of patients with multiple myeloma whoa re refractory or have relapsed with standard therapy.”
What We’re Seeing From The Stock
While the news that was released today is overwhelmingly positive, Adaptimmune Therapeutics simply isn’t having the best of days in the market. Unfortunately, the stock has seen steady declines after strong pre-market growth. Currently (10:17), ADAP is trading at $4.84 per share after a loss of $0.07 per share, or 1.43%.
What We Can Expect To See Ahead
Moving forward, I’m expecting to see quite a bit of positivity out of ADAP stock. First and foremost, when investors start to see the PR, I’m expecting to see excitement leading to gains that could happen as soon as today. Additionally, in the long run, my opinion is still very bullish. At the end of the day, Adaptimmune is doing great things with the NY-ESO SPEAR T-cell therapy, and the fact that Merck is now collaborating with them further validates their efforts. All in all, I’m expecting to see gains in ADAP ahead.
Don’t waste your time! Click here to find winning trades in minutes!
Never Miss The News Again!
Do you want real-time, actionable news delivered directly to your inbox? Join the CNA Finance mailing list below!
[Image Courtesy of Wikipedia]